Cabazitaxel in prostate cancer: stretching a string

Lancet. 2010 Oct 2;376(9747):1119-20. doi: 10.1016/S0140-6736(10)61510-3.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cancer Vaccines / administration & dosage
  • Cancer Vaccines / pharmacology
  • Clinical Trials as Topic
  • Docetaxel
  • Drug Approval
  • Drug Resistance, Neoplasm*
  • Estramustine / administration & dosage
  • Humans
  • Male
  • Mitoxantrone / administration & dosage
  • Prednisone / administration & dosage
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology
  • Quality of Life
  • Taxoids / administration & dosage
  • Taxoids / therapeutic use*
  • Tissue Extracts / administration & dosage
  • Tissue Extracts / pharmacology

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Hormonal
  • Cancer Vaccines
  • Taxoids
  • Tissue Extracts
  • Docetaxel
  • Estramustine
  • cabazitaxel
  • sipuleucel-T
  • Mitoxantrone
  • Prednisone